Zhuang Yong, Hu Xin, Cai Qingyan, Huang Huibin, Yang Xinna
Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Fengze District, Quanzhou City, Fujian Province, China.
Sci Rep. 2025 Jul 1;15(1):20728. doi: 10.1038/s41598-025-07665-4.
While Glycoantigen 724 (CA72-4) is well-established as a tumor marker, its association with gout has yet to be fully explored. Our study aimed to investigate the expression levels of CA72-4 and other tumor markers at different stages of gout in patients and to assess any changes in their expression levels following treatment with colchicine. For this observational clinical study, participants with gout were recruited and divided into two groups: a gout-flare group and a gout-no-flare group. Additionally, healthy volunteers were recruited as controls. The clinical characteristics of the three groups were compared, and the ROC curve was used to compare the diagnostic value of C-reactive protein (CRP) and CA72-4 for gout flare. Gout flare is divided into two subgroups: a group receiving colchicine and a group receiving without colchicine; comparing the clinical characteristics of the two groups. Serum CA72-4 levels were significantly higher in gout flare compared to gout no flare and healthy controls (P < 0.01). There was no significant difference regarding other tumor markers (Glycoantigen 125 (CA12-5), Glycoantigen 199 (CA19-9), and Carcinoembryonic antigen (CEA)) among the various groups. Elevated levels of CA72-4 and CRP, BMI, and tophi were independent correlates of acute gout attacks (OR = 1.438, 95% CI: 1.240 ~ 1.668, P < 0.01; OR = 1.533, 95% CI: 1.282～1.834, P < 0.01; OR = 3.368, 95% CI: 1.229～9.230, P = 0.018; OR = 1.451, 95% CI: 1.020～2.064, P = 0.038). ROC curve analysis showed that CA72-4 had a higher area under the curve compared to CRP (AUC = 0.966, 95% CI: 0.944～0.981, P < 0.01; AUC = 0.900, 95% CI: 0.867～0.927, P < 0.01). However, serum CA72-4 levels were further elevated during gout flare in the group receiving colchicine (P < 0.01). During gout flare, serum CA72-4 levels were significantly elevated. Serum CA72-4 and CRP can be considered diagnostic serum markers for the acute phase of gout. Colchicine can cause further elevation of serum CA72-4 in gouty flares.
虽然糖抗原724（CA72-4）作为一种肿瘤标志物已得到充分确立，但其与痛风的关联尚未得到充分研究。我们的研究旨在调查痛风患者不同阶段CA72-4及其他肿瘤标志物的表达水平，并评估秋水仙碱治疗后其表达水平的任何变化。对于这项观察性临床研究，招募了痛风患者并将其分为两组：痛风发作组和痛风未发作组。此外，招募健康志愿者作为对照。比较了三组的临床特征，并使用ROC曲线比较C反应蛋白（CRP）和CA72-4对痛风发作的诊断价值。痛风发作分为两个亚组：一组接受秋水仙碱治疗，一组未接受秋水仙碱治疗；比较两组的临床特征。与痛风未发作组和健康对照组相比，痛风发作组血清CA72-4水平显著更高（P<0.01）。各亚组中其他肿瘤标志物（糖抗原125（CA12-5）、糖抗原199（CA19-9）和癌胚抗原（CEA））无显著差异。CA72-4、CRP水平升高、BMI和痛风石是急性痛风发作的独立相关因素（OR=1.438，95%CI：1.240～1.668，P<0.01；OR=1.533，95%CI：1.282～1.834，P<0.01；OR=3.368，95%CI：1.229～9.230，P=0.018；OR=1.451，95%CI：1.020～2.064，P=0.038）。ROC曲线分析显示，与CRP相比，CA72-4曲线下面积更高（AUC=0.966，95%CI：0.944～0.981，P<0.01；AUC=0.900，95%CI：0.867～0.927，P<0.01）。然而，接受秋水仙碱治疗组痛风发作期间血清CA72-4水平进一步升高（P<0.01）。痛风发作期间，血清CA72-4水平显著升高。血清CA72-4和CRP可被视为痛风急性期的诊断血清标志物。秋水仙碱可导致痛风发作时血清CA72-4进一步升高。
Zotero 插件